The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
J Neuropsychiatry Clin Neurosci 19:318-325, August 2007
doi: 10.1176/appi.neuropsych.19.3.318
© 2007 American Neuropsychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Abstract Freely available
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Rentzos, M.
* Articles by Vassilopoulos, D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Rentzos, M.
* Articles by Vassilopoulos, D.
Related Collections
* Alzheimer's Disease
* Dementias (General)

Circulating Interleukin-15 in Dementia Disorders

Michael Rentzos, M.D., George P. Paraskevas, M.D., Elisabeth Kapaki, M.D., Chryssoula Nikolaou, M.D., Margarita Zoga, M.D., Anthousa Tsoutsou, M.D., Antonis Rombos, M.D. and Demetrios Vassilopoulos, Ph.D.

Received May 9, 2006; revised August 5, 2006; accepted August 21, 2006. Drs. Rentzos, Paraskevas, Kapaki, Rombos, and Vassilopoulos are affiliated with the Department of Neurology, Aeginition Hospital, Athens National University, School of Medicine, Athens, Greece. Drs. Nikolau, Zoga, and Tsoutsou are affiliated with the Department of Immunology, Aeginition Hospital, Athens National University, School of Medicine, Athens, Greece. Address correspondence to Dr. Rentzos, Aeginition Hospital, Athens National University, School of Medicine, 72–74 Vas. Sophias Avenue, Athens 11528, Greece; mrentzos{at}med.uoa.gr (e-mail).


  ABSTRACT

 
TOP
 ABSTRACT
INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 REFERENCES
 
The objective of this study was to assess the role of interleukin-15 (IL-15) as a potential marker of immune reactions in patients with Alzheimer’s disease and vascular dementia. The authors measured by immunoassay serum IL-15 levels in 20 patients with Alzheimer’s disease and 15 patients with vascular dementia and compared them with serum IL-15 levels in 15 healthy subjects. The authors also studied the effect of treatment with acetylcholinesterase inhibitors (AChEI) on serum IL-15 levels. Patients with Alzheimer’s disease were found to have significantly lower serum IL-15 levels compared with healthy subjects and patients with vascular dementia. Healthy subjects and patients with vascular dementia did not differ between each other. Age, sex, disease duration, and Mini-Mental State Examination score did not affect IL-15 levels in any of the groups. Treatment with AChEI had no influence on IL-15 concentrations. The findings suggest that IL-15 is not implicated in the pathogenetic mechanisms of Alzheimer’s disease and vascular dementia. An immune hyporesponsiveness at some point during disease development may be responsible for the lower levels of IL-15 and other cytokines in Alzheimer’s disease patients.


  INTRODUCTION

 
TOP
 ABSTRACT
 INTRODUCTION
METHOD
 RESULTS
 DISCUSSION
 REFERENCES
 
Interleukin-15 is a proinflammatory cytokine produced by activated blood monocytes, macrophages, dendritic cells, and activated glial cells.1–3 It promotes T cell proliferation and induction of cytolytic effector cells, including natural killer and cytotoxic cells, and stimulates B-cells to proliferate and secrete immunoglobulins.4,5

The brain is now recognized as having its own innate immune system6 and sharing a variety of bioactive molecules with the peripheral immune system. Morphological "delegates" of the immune system, the microglial cells, are present in the brain, and, respectively, the peripheral lymphoid organs are innervated.7 These findings have led to the view that the brain and the immune system speak a common biochemical language.8 The exchange of signals between immune and neural cells may lead to dysregulation of cytokine release.9

Alzheimer’s disease is a neurodegenerative disorder resulting in major cognitive decline. The main pathological hallmarks are the numerous senile plaques, the neurofibrillary tangles, and the cerebrovascular amyloidosis in various regions of the brain.10 Aß amyloid, a protein derived from beta-site proteolytic processing of the amyloid precursor protein, is the major component of senile plaques.11 Inflammatory responses have been implicated in the pathogenesis of Alzheimer’s disease and deposition of Aß amyloid. Lesions of Alzheimer’s disease are associated with low-grade but sustained inflammatory responses.12 Activated microglia have been demonstrated in pathological lesions in several neurological diseases, including Alzheimer’s disease.13,14 The presence of the acute phase proteins {alpha}1-antichymotrypsin, {alpha}2 macroglobulin ({alpha}2-M), C-reactive protein, and proinflammatory cytokines interleukin-6 and interleukin-1 in senile plaques has also been demonstrated.15–18 Adhesion molecules are presumably involved in brain tissue lesions of patients with Alzheimer’s disease.10,19 Cells exposed to proinflammatory cytokines have elevated levels of amyloid precursor protein, which may result in increased production of Aß and further plaque formation.20

To clarify whether IL-15 is involved in the possible inflammatory reactions of Alzheimer’s disease and other dementias as a marker of proinflammatory activation, we measured serum IL-15 levels in patients with Alzheimer’s disease and vascular dementia compared with healthy subjects. We decided to include patients with vascular dementia because Alzheimer’s disease and vascular dementia are the most common senile dementias. Cerebrovascular pathology increases the risk of developing Alzheimer’s disease and is involved in mechanisms of its progression.21 Vascular risk factors interact with apolipoprotein (APO) E {epsilon}4 to increase the risk of Alzheimer’s disease beyond that of APOE {epsilon}4 alone.22,23 The vascular component of Alzheimer’s disease is important and potentially treatable.24 Therefore, treatment of vascular risk factors may prevent Alzheimer’s disease or delay its progression.

Previous studies25,26 have demonstrated a link between cholinergic activation and amyloid precursor protein metabolism. The potentiation of central cholinergic activity has been proposed as a therapeutic approach for improving the cognitive function in Alzheimer’s disease patients.27,28 Results of recent studies suggest that treatment with acetylcholinesterase inhibitors in Alzheimer’s disease patients modulates the expression and production of proinflammatory and anti-inflammatory cytokines.9,29,30 To assess the contribution of achetylcholinesterase inhibitors in the modulation of cytokine network presumably involved in Alzheimer’s disease neurodegeneration, we measured serum IL-15 levels before and 4 months after treatment with a regimen of donepezil (10 mg/day).


  METHOD

 
TOP
 ABSTRACT
 INTRODUCTION
 METHOD
RESULTS
 DISCUSSION
 REFERENCES
 
A total of 50 subjects were enrolled in the study, divided in 3 groups: 1) the Alzheimer’s disease group comprised 20 patients with probable Alzheimer’s disease, diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria;31 2) the vascular dementia group comprised 15 patients diagnosed according to the National Institute of Neurological Disorders and Stroke and the Association Internazionale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) and Hachinski Ischemic Scale (HIS);32,33 3) the comparison group comprised 15 healthy individuals. Patients with evidence of systemic inflammation on clinical examination or serum biochemical tests (increased number of white blood cells, elevated C-reactive protein, elevated erythrocyte sedimentation rate) were excluded. Patients with use of nonsteroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, steroids, or statins during the last 2 months before enrollment were also excluded from the study.

Sample Collection and IL-15 Assay
Serum concentrations of circulating IL-15 were measured by immunoassay using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R and D Systems, Minneapolis, Minn.). Serum samples diluted 1:3 were added in duplicate to microtiter wells and assayed according to routine procedures. Optical densities were determined by means of a micro-ELISA reader (L.P 400, Pasteur Diagnostics). Values were calculated by comparison with a standard curve that was generated with IL-15 standards. The limit of detection was 2 pg/ml.

Statistical Analysis
All variables were tested for normality and homogeneity of variances by the Shapiro-Wilk’s and Leven’s tests, respectively. We observed significant deviation from normality and heterogeneity of variances in IL-15. However, logarithmic transformation restored the above violations to some degree and permitted the use of analysis of covariance (ANCOVA), with diagnostic group and sex as factors and age as covariates, followed by Newman-Keuls post-hoc tests. The results were confirmed by a Kruskal-Wallis test of original data, followed by Dunn’s post-hoc tests. The effects of age, duration of the disease, dementia severity, and sex on serum IL-15 levels were also tested separately in each group by the Spearman correlation coefficient and Mann-Whitney U test. We used repeated-measures ANOVA to compare pre- and posttreatment levels of IL-15 in Alzheimer’s disease log-transformation and confirmed them by Wilcoxon matched-pairs test.


  RESULTS

 
TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
DISCUSSION
 REFERENCES
 
Results are summarized in Table 1 and plotted in Figure 1. Age, sex, duration of the disease, and Mini-Mental State Examination (MMSE) score did not affect serum IL-15 levels in any of the studied groups. ANCOVA, for logarithmically transformed IL-15 levels, revealed a significant effect of diagnostic group, but not of sex or age. Baseline IL-15 in Alzheimer’s disease was significantly lower compared with both healthy subjects and patients with vascular dementia; healthy subjects and vascular dementia patients did not differ between each other. Nonparametric comparison of original baseline data confirmed the above results (Kruskal-Wallis test, p=0.0009, with reduced IL-15 in Alzheimer’s disease at the 0.05 level). For Alzheimer’s disease patients, no significant change of serum IL-15 was noted 4 months posttreatment with donepezil, the repeated measures ANOVA model being unaffected by age, sex, and the degree of clinical response.


View this table:
[in this window]
[in a new window]

 

TABLE 1. Clinical and Biochemical Data of the Studied Groups




Figure 1
View larger version (35K):
[in this window]
[in a new window]

 

FIGURE 1.  Scatterplot of Serum IL-15 Levels in the Studied Groups

Horizontal bars indicate median values


The precise role of the cytokines in the neuropathology of Alzheimer’s disease has yet to be clarified. In Table 2, we compare IL-15 with other, better studied circulating cytokines in Alzheimer’s disease and other dementias with regards to their source, potential role in pathogenesis, and changes in their level with age and severity of disease.


View this table:
[in this window]
[in a new window]

 

TABLE 2. Cytokines in Alzheimer's Disease and Other Dementia Disorders




  DISCUSSION

 
TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we investigated serum levels of IL-15 as potential markers of inflammatory reactions in patients with Alzheimer’s disease and vascular dementia. Our data contradict the proinflammatory hypothesis since patients with Alzheimer’s disease had reduced serum IL-15 concentrations compared with the healthy group (Figure 1). A significant decrease of interleukin-1beta and interleukin-6 secretion has been observed in severely demented patients34 after lipopolysaccharide-stimulation of blood cells of Alzheimer’s disease patients with different disease severity. In another study, it has been shown that TNF-{alpha} release from blood cells is significantly decreased in demented patients compared to healthy subjects.35 Our findings in the serum of Alzheimer’s disease patients come to support these latter results but seem to contrast with the conclusions of other recent reports which suggest an increased production36 or increased circulation of cytokines.37 Circulating cytokines have a short half-life, act mainly in an autocrine or paracrine fashion, may reach high concentrations at sites of release but much lower concentrations after dilution in blood, or they may bind to molecules that do not permit their detection by immunological methods.38 All of these possibilities may factor into the contradictory results of several studies. An immune hyporesponsiveness to human Aß has been found in amyloid precursor protein transgenic mice.39 Patients with chronic exposure of the immune system to Aß could have reduced immune responses, and this may explain why severely demented patients have reduced cytokine release. The low IL-15 serum levels in our patients with Alzheimer’s disease may indicate the existence of an effective mechanism that dampens the inflammatory response. The hyperactivity of the hypothalamus-pituitary-adrenal axis in Alzheimer’s disease patients leading to cortisol hypersecretion40 may contribute to this phenomenon since glucocorticoids are potent inhibitors of cytokine production.41 However, no correlation between serum IL-15 levels and duration or severity of the disease has been found in our study. This seems in contrast with other studies suggesting that the levels of other cytokines like TNF-{alpha} or IL-6 may be correlated with disease severity.38 It is possible that IL-15 is not a marker of disease duration or severity.

Cytokines found in plasma or serum may be produced by blood cells, endothelium, or may originate from the brain. Activated by Aß amyloid accumulation, blood cells may cross the blood-brain barrier and contribute to Alzheimer’s disease degeneration.42,43 In contrast, inflammatory molecules produced in the brains of demented patients may result in an inflammatory response in the periphery by humoral, neuroendocrine, and sympathetic connections that have been clearly demonstrated.44–46 To clarify the issue of the source of circulating IL-15, its expression and production by activated blood mononuclear cells should be assessed.

There is evidence that inflammatory mechanisms are implicated in patients with cerebrovascular disease. The onset of cerebral ischemia may trigger a cascade of proinflammatory molecular and cellular events.47 Some biochemical inflammatory markers, such as Erythrocyte Sedimentation Rate, levels of C-reactive protein, IL-6, S100ß, intercellular adhesion molecule-1 (ICAM-1) and matrix metalloproteinase-9 (MMP-9), may be associated with early signs of ischemia in the neuroimage, with early and late clinical outcome, with the volume of the infarct, with hemorrhagic transformation, and with the efficacy of thrombolytic therapy.48–50 In patients with cerebral infarct, an increase was found in the levels of acute phase proteins like C-reactive protein, fibrinogen, {alpha}-1 antitrypsin, and acidic {alpha}-1 glycoprotein, suggesting that ischemic necrosis is associated with inflammatory reactions.50 Ischemia and hypoxia in vascular dementia patients could lead to the degeneration of nerve fibers.51,52 The activation of glial cells for clearance of damaged tissue could lead to the production of cytokines like IL-1, IL-2, IL-6 and TNF-{alpha}. In our study serum IL-15 levels were not different in patients with vascular dementia compared to healthy subjects. By visual inspection of the data (Figure 1), it seems that some patients with vascular dementia have low IL-15 levels in the range of those with Alzheimer’s disease and the rest have higher levels in the range of healthy subjects. It is possible that patients with low levels of IL-15 have mixed dementia since it is known that many patients with the diagnosis of either Alzheimer’s disease or vascular dementia based on clinical examination have been proved to suffer from mixed dementia. Available data in the literature concerning cytokines and vascular dementia are contradictory and do not allow definite conclusions.38,53,54 It is obvious that more comprehensive clinical trials need to be carried out before firm conclusions can be drawn concerning discrimination of dementias based on proinflammatory cytokines serum profiles.

Acetylcholine is synthesized by lymphocytes and released from activated T-cells into the vicinity of acetylcholine receptors of target cells, interacting with the receptors before hydrolysis by AchE.55–58 Recent investigations have provided evidence that peripheral blood mononuclear cells possess most of the essential components needed to constitute a cholinergic system.59 Acetylcholine synthesized and released from peripheral blood mononuclear cells may act as an immunomodulator.56,60 AChEI in our Alzheimer’s disease patients had not changed significantly serum IL-15 concentrations. IL-15 may act in a different way or may not be produced at the same time regarding other proinflammatory cytokines like IL-1ß or TNF-{alpha}. In the present study, serum IL-15 levels were measured 4 months after onset of AChEI therapy instead of after 1 month in other recent studies.9,30 It is possible that the change of serum concentrations of IL-15 and other cytokines after treatment with AchEI, suggesting a remodelling of cytokine network, is not a lasting process. Specific mechanisms blocking the inflammatory response after an initial stimulation may be involved. It is difficult to clarify the exact role of so many inflammatory molecules, including cytokines, in the inflammatory responses that may be involved in the pathogenesis of dementias. Therefore, the failure of AChEI to influence IL-15 production does not exclude the possible correlation between the cholinergic system and immune responses in Alzheimer’s disease patients.

Achetylcholinesterase inhibitors appear to increase acetylcholine bioavailability but it is not completely known how they exert their probable neuroprotective action. Recent reports suggest that accumulation of Aß amyloid and proinflammatory cytokines during aging may generate in the brain a "neurotrophin resistance" state that places the brain at risk for cognitive decline and dementia.61

To our knowledge, this is the first study in which serum IL-15 concentrations are assessed in patients with dementia disorders, such as Alzheimer’s disease and vascular dementia. It has some weaknesses, as do all studies that measure cytokine levels and relate them to the pathogenesis of dementia. Increases or decreases in cytokine levels, if they occur, may be transient or may differ according to the stage of illness. Hence, it would be important in future experiments to examine levels serially to know whether levels are stable or show periods of great increase or decrease. The half-life of cytokines may also differ. Therefore, similar increases or decreases in the production of cytokines at one moment may be associated with significantly different levels measured at a particular later time. Hence, single measures may not indicate levels over time. Immune markers can be synthesized in the CNS, in peripheral blood, or can be made by cells in one location that move to the other. Ultimately, the important levels for neurodegenerative disorders are in the CNS. In one recent study,62 patients with Alzheimer’s disease and frontotemporal dementia had significantly higher CSF IL-15 levels compared with patients suffering from noninflammatory neurological diseases.62 This may suggest an intrathecal IL-15 production. A possible explanation for these results (high CSF IL-15 levels in one study and low serum IL-15 levels in the other) is that we used patients with other noninflammatory neurological diseases in one study and healthy subjects as comparators in the other. Hence, it is not possible to exclude a potential impact of other neurological diseases on intrathecal cytokine production. It would be important to measure simultaneously CSF and serum IL-15 levels in the same patients in order to assess whether they are related.

Future studies of a greater number of patients that assess circulating cytokines in serum and CSF and/or cytokine levels in various regions of CNS by immunohistochemical methods must be carried out in order to investigate the peripheral or glial source of IL-15 and other cytokines in patients with dementias and to clarify the hypothesis of immune activation as part of the pathogenetic mechanisms in these disorders.


  REFERENCES

 
TOP
 ABSTRACT
 INTRODUCTION
 METHOD
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Doherty TM, Seder RA, Sher A: Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996; 156:735–741[Abstract]
  2. Jonuleit H, Wiedemann K, Muller G, et al: Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells. J Immunol 1997; 160:2610–2615
  3. Lee YB, Satoh J, Walker DG, et al: Interleukin-15 gene expression in human astrocytes and microglia in culture. Neuroreport 1996; 7:1062–1066[Medline]
  4. Carson WE, Giri JG, Lindemann MJ, et al: IL-15 is a novel cytokine that activates human NK cells via components of IL-2 receptor. J Exp Med 1994; 180:1395–1405[Abstract/Free Full Text]
  5. Grabstein KH, Eisenmann J, Shanebeck K, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965–968[Abstract/Free Full Text]
  6. Uchikado H, Akiyama H, Kondo H, et al: Activation of vascular endothelial cells and perivascular cells by systemic inflammation—an immunohistochemical study of postmortem human brain tissues. Acta Neuropathol 2004; 107:341–351[CrossRef][Medline]
  7. Eikelenboom P, Hoogendijk WJG, Jonker C, et al: Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer’s disease. J Psychiatr Res 2002; 36:269–280[CrossRef][Medline]
  8. Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15:504–511[CrossRef][Medline]
  9. Gambi F, Reale M, Iarlori C, et al: Alzheimer’s patients treated with an ACHE inhibitor show higher IL-4 and lower IL-1ß levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 2004; 24:314–321[CrossRef][Medline]
  10. Verbeek MM, Otte-Holler I, Westphal JR, et al: Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer’s disease. Am J Pathol 1991; 144:104–116
  11. Hussain L, Powell D, Howlett D et al: Identification of a novel aspartic protease (Asp2) as [beta]-secretase. Mol Cell Neurosci 1999; 14:419–427[CrossRef][Medline]
  12. Akiyama H, Arai T, Kondo H, et al: Cell mediators of inflammation in the Alzheimer’s disease brain. Alzheimer Dis Assoc Disord 2000; 14(suppl):S47-S53
  13. McGeer PL, Kawamata T, Walker DG, et al: Microglia in degenerative neurological disease. Glia 1993; 7:84–92[CrossRef][Medline]
  14. Yong BL, Atsushi N, Seung UK: Cytokines, chemokines and cytokine receptors in human microglia. J Neurosci Res 2002; 69:94–103[CrossRef][Medline]
  15. Schnabel J: New Alzheimer’s therapy suggested. Science 1993; 260:1719–1720[Free Full Text]
  16. Shoji M, Hirai S, Yamaguchi H, et al: Alpha 1-antichymotrypsin is present in diffuse senile plaques. Am J Pathol 1991; 138:247–257[Abstract]
  17. Strauss S, Bauer J, Ganter U, et al: Detection of interleukin-6 and {alpha}-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer’s disease patients. Lab Invest 1992; 66:223–230[Medline]
  18. Vandenabeele P, Fiers W: Is amyloidogenesis during Alzheimer’s disease due to an IL-1/IL-6-mediated "acute phase response" in the brain? Immunol Today 1991; 12:217–219[CrossRef][Medline]
  19. Rentzos M, Michalopoulou M, Nikolaou C, et al: The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 2005; 228:129–135[CrossRef][Medline]
  20. Chao CC, Hu S, Ehrlich L, et al: Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 1995; 9:355–365[CrossRef][Medline]
  21. Hachinski V, Munoz DG: Cerebrovascular pathology in Alzheimer’s disease: cause, effect or epiphenomenon? Ann N Y Acad Sci 1997; 826:1–6[CrossRef][Medline]
  22. Carmelli D, Swan GF, Reed T, et al: Midlife cardiovascular risk factors, APOE, and cognitive decline in elderly male twins. Neurology 1998; 50:1580–1585[Abstract]
  23. Haan MN, Shemanski I, Jagust WJ, et al: The role of APOE {epsilon}4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999; 282:40–46[Abstract/Free Full Text]
  24. Jagust W: Untangling vascular dementia. Lancet 2001; 358:2097–2098[CrossRef][Medline]
  25. Inestrosa NC, Alvarez A, Perez CA, et al: Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16:881–891[CrossRef][Medline]
  26. Mesulam MM: Alzheimer’s plaques and cortical cholinergic innervation. Neuroscience 1986; 17:275–276[CrossRef][Medline]
  27. Feldman H, Gauuthier S, Hecker J for the Donepezil Study Group: Benefits of donepezil on global function, behaviour, cognition, and ADLs in patients with moderate-to-severe Alzheimer’s disease. Neurology 2000; 54(suppl 13):A469
  28. Mohs R, Doody RS, Morris J: A1-year placebo-controlled preservation of function survival study of donepezil in Alzheimer’s disease patients. Neurology 2001; 5:481–488
  29. Lugaresi A, Di Iorio A, Iarlori C, et al: IL-4 in vitro production is upregulated in Alzheimer’s disease patients treated with acetylcholinesterase inhibitors. Exp Gerontol 2004; 39:653–657[CrossRef][Medline]
  30. Reale M, Iarlori C, Gambi F, et al: Treatment with an acetylcholinesterase inhibitor in Alzheimer’s patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 2004; 148:162–171[CrossRef][Medline]
  31. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer’s disease. Neurology 1984; 34:939–944[Abstract/Free Full Text]
  32. Hachinski VC, Iliff LD, Zilh E, et al: Cerebral blood flow in dementia. Arch Neurol 1975; 32:632–637[Abstract/Free Full Text]
  33. Roman GC, Tatemichi TK, Erkinjunti T, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop. Neurology 1993; 43:250–260[Abstract/Free Full Text]
  34. Sala G, Galimberti G, Carnevari C, et al: Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 2003; 24:909–914[CrossRef][Medline]
  35. De Luigi A, Fragiacomo C, Lucca U, et al: Inflammatory markers in Alzheimer’s disease and multi-infarct dementia. Mech Ageing Dev 2001; 122:1985–1995[CrossRef][Medline]
  36. Lombardi VR, Garcia M, Rey L, Cacabelos R: Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (Alzheimer’s disease) individuals. J Neuroimmunol 1999; 97:163–171[CrossRef][Medline]
  37. Singh V, Guthikonda P: Circulating cytokines in Alzheimer’s disease. J Psych Res 1997; 31:657–660[CrossRef]
  38. De Luigi A, Pizzimenti S, Quadri P, et al: Peripheral inflammatory response in Alzheimer’s disease and multiinfarct dementia. Neurobiol Dis 2002; 11:308–314[CrossRef][Medline]
  39. Monsonego A, Maron R, Zota V, et al: Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. PNAS 2001; 98:10273–10278[Abstract/Free Full Text]
  40. Hatzinger M, Z’Brun A, Hemmeter U, et al: Hypothalamic-pituitary-adrenal system function in patients with Alzheimer’s disease. Neurobiol Aging 1995; 16:205–209[CrossRef][Medline]
  41. Wiegers GJ, Reul JM: Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci 1998; 19:317–321[CrossRef][Medline]
  42. Szczepanic AM, Rampe D, Ringheim GE: Amyloid-beta peptide fragment p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem 2001b; 77:304-317
  43. Yates SI, Burgess LH, Kocsis-Angle J, et al: Amyloid beta and myelin fibers include increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 2000; 74:1017–1025[CrossRef][Medline]
  44. De Luigi A, Terreni I, Sironi M, et al: The sympathetic nervous system tonically inhibit peripheral interleukin-1ß and interleukin-6 induction by central lipopolysaccharide. Neuroscience 1998; 83:1245–1250[CrossRef][Medline]
  45. De Simoni MG, Del Bo R, De Luigi A, et al: Central endotoxin induces different patterns of interleukin-1beta and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995; 136:897–902[Abstract]
  46. De Simoni MG, Sironi M, De Luigi A, et al: Intracerebroventricular injection of interleukin-1 induces high circulating levels of interleukin-6. J Exp Med 1990; 171:1773–1778[Abstract/Free Full Text]
  47. Chamorro A: Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004; 17(suppl 3):1-5
  48. Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers brain ischemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004; 17(suppl 1):7-18
  49. Lynch JR, Blessing R, White WD, et al: Novel diagnostic test for acute stroke. Stroke 2004; 35:57–68[Abstract/Free Full Text]
  50. Bartosik-Psujek H, Belniak E, Stelmasiak Z: Markers of inflammation in cerebral ischemia. Neurol Sci 2003; 24:279–280[CrossRef][Medline]
  51. Jia JP, Meng R, Sun YX, et al: Cerebrospinal fluid tau, Aß1-42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 2005; 383:12–16[CrossRef][Medline]
  52. Stys PK, Jiang Q: Calpain-dependent neurofilament breakdown in anoxic and ischemic rat central axons. Neurosci Lett 2002; 328:150–154[CrossRef][Medline]
  53. Cacabelos R, Alvarez XA, Franco-Maside A, et al: Serum tumor necrosis factor (TNF) in Alzheimer’s disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994; 16:29–35[Medline]
  54. Paganelli R, Di Iorio A, Patricelli L, et al: Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer’s disease patients. Exp Gerontol 2002; 37:257–263[CrossRef][Medline]
  55. Inestrosa NC, Alarcon R, Arriagada J, et al: Blood markers in Alzheimer’s disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J Neurol Sci 1994; 122:1–5[CrossRef][Medline]
  56. Kawashima K, Fujii T: The lymphocytic cholinergic system and its biological function. Life Sci 2003; 72:2101–2109[CrossRef][Medline]
  57. Kawashima K, Fujii T: Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86:29–48[CrossRef][Medline]
  58. Kawashima K, Fujii T, Watanabe Y, et al: Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci 1998; 62:1701–1705[CrossRef][Medline]
  59. Chao CC, Molitor TW, Hu S: Neuroprotective role of IL-4 against activated microglia. J Immunol 1993; 151:1473–1481[Abstract]
  60. Tayebati SK, Amenta F, Amici S, et al: Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer’s disease: a marker of cholinergic dysfunction? J Neuroimmunol 2001; 121:126–131[CrossRef][Medline]
  61. Cotman CW: The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 2005; 30:877–881[CrossRef][Medline]
  62. Rentzos M, Zoga M, Paraskevas GP, et al: IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006; 19:114–117[Abstract/Free Full Text]




This Article
* Abstract Freely available
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Rentzos, M.
* Articles by Vassilopoulos, D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Rentzos, M.
* Articles by Vassilopoulos, D.
Related Collections
* Alzheimer's Disease
* Dementias (General)

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org